Adopting a systems approach, we devise a general workflow to define actionable subtypes in human cancers. Applied to small 2 cell lung cancer (SCLC), the workflow identifies four subtypes based on global gene expression patterns and ontologies. Three 3 correspond to known subtypes, while the fourth is a previously undescribed neuroendocrine variant (NEv2). Tumor 4 deconvolution with subtype gene signatures shows that all of the subtypes are detectable in varying proportions in human and 5 mouse tumors. To understand how multiple stable subtypes can arise within a tumor, we infer a network of transcription 6 factors and develop BooleaBayes, a minimally-constrained Boolean rule-fitting approach. In silico perturbations of the 7 network identify master regulators and destabilizers of its attractors. Specific to NEv2, BooleaBayes predicts ELF3 and 8 NR0B1 as master regulators of the subtype, and TCF3 as a master destabilizer. Since the four subtypes exhibit differential 9 drug sensitivity, with NEv2 consistently least sensitive, these findings may lead to actionable therapeutic strategies that 10 consider SCLC intratumoral heterogeneity. Our systems-level approach should generalize to other cancer types.
Introduction 26
A major barrier to effective cancer treatment is the occurrence of heterogeneous cell subpopulations that arise within a tumor 27 via genetic or non-genetic mechanisms. Clonal evolution of these subpopulations via plasticity, drug-induced selection, or Materials and methods 73 Data 74 Human SCLC cell line data was taken from the Broad Institute's CCLE RNA-seq expression data (version from February 14, 75 2018) at https://portals.broadinstitute.org/ccle/data. 81 human tumors were obtained from George et al. dataset, courtesy of 76 R.K. Thomas [5] . The Myc-high mouse data set [15] was obtained from the NCBI GEO deposited at GSE89660. PDX/CDX 77 mouse data [18] was obtained from the NCBI GEO deposited at GSE110853. Data was subsetted to only include SCLC cell 78 lines (50). Features with consistently low read counts (< 10 in all samples) and non-protein-coding genes were removed. All 79 expression data was then converted to TPM units and log1p normalized by dataset. 80 Clustering and WGCNA 81 We applied Consensus Clustering to RNA-seq gene expression data from the 50 SCLC cell lines in the Cancer Cell Line 82 Encyclopedia (CCLE) using the ConsensusClusterPlus R package [19] . Gene expression (TPM) was median-centered prior to 83 clustering, and we clustered the cell lines using a k-means method with a Pearson distance metric for k ∈ {2, 12} (S1 Fig) . 84 Other parameters were set as follows: reps = 1000, pItem = 0.8, pFeature = 0.8, seed = 1. Best k value was chosen 85 heuristically based on the cumulative distributive function plot (S1 Fig, tracking plot, delta area plot, and average consensus 86 scores (not shown). 87 To identify gene programs driving the distinction between the four SCLC phenotypic clusters, we performed weighted gene 88 co-expression network analysis (WGCNA) on the same RNA-seq data. The softPower threshold was chosen as 12 to generate 89 a signed adjacency matrix from gene expression. A topological overlap matrix (TOM) was created using this adjacency 90 matrix as input. Hierarchical clustering on 1-TOM using method = 'average,' and the function cutTreeDynamic was used to 91 find modules with parameters: deepSplit=2, pamRespectsDendro=TRUE, minClusterSize=100. These settings were chosen 92 based on an analysis of module stability and robustness. We then computed an ANOVA comparing the four subtypes for each 93 module. 11 out of 18 modules were able to statistically distinguish between the four clusters with an FDR-adjusted p-value < 94 0.05. 95 Gene Ontology Enrichment Analysis 96 We ran a gene ontology (GO) enrichment analysis on each module that was significantly able to distinguish the phenotypes 97 (11 total) . The terms that were significantly enriched in at least one module were culminated into a general list of terms 98 enriched in SCLC, which had 1763 terms. To visualize these terms, we computed a distance matrix between pairs of GO 99 terms using GoSemSim [20] , and used this matrix to project the terms into a low dimensional space using t-SNE. t-SNE is a 100 popular method that computes a low-dimensional embedding of data points and seeks to preserve the high-dimensional 101 distance between points in the low-dimensional space. 102 
Drug Sensitivity Analysis 103
Our drug sensitivity analysis used the freely available drug screen data from Polley, et al [21] . This screen included 103 Food 104 and Drug Administration-approved oncology agents and 423 investigational agents on 63 human SCLC cell lines and 3 efficacy and potency of a drug when added to each cell line. By segregating the cell lines by subtype, we were able to evaluate 117 the relationship between drug response and subtype. Further information is available at https://docs.thunor.net/. 118 
CIBERSORT

119
CIBERSORT is a computational inference tool developed by Newman et al. at Stanford University [4] . We utilized the 120 interactive user interface of CIBERSORT Jar Version 1.06 at https://cibersort.stanford.edu/runcibersort.php. Gene 121 signatures were automatically determined by the software from a provided sample file with a matching phenotype class file. 122 For this sample file and class file, the RNA-seq data from 50 human SCLC cell lines were inputted with their consensus 123 clustering class labels. For each run, 500 permutations were performed. Relative and absolute modes were run together, with 124 quantile normalization disabled for RNA-seq data, kappa = 999, q-value cut-off = 0.3, and 50-150 barcode genes considered 125 when building the signature matrix.
126
Single cell RNA sequencing of TKO SCLC tumors 127 The p53, Rb and p130 triple-knockout (TKO) SCLC mouse model with the Rosa26membrane-Tomato/membrane-GFP 128 (Rosa26mT/mG) reporter allele has been described (Denny and Yang et al., 2016) . Tumors were induced in 8-weeks old TKO; 129 Rosa26mT/mG mice by intratracheal administration of 4x107 PFU of Adeno-CMV-Cre (Baylor College of Medicine, Houston, 130 TX). 7 months after tumor induction, single tumors (one tumor each from two mice) were dissected from the lungs and 131 digested to obtain single cells for FACS as previously described [10, 23] . DAPI-negative live cells were sorted using a 100 µm 132 nozzle on a BD FACSAria II, spundown and resuspended in PBS with 10% bovine growth serum (Fisher Scientific) at a 133 concentration of 1000 cells/µl. Single cell capture and library generation was performed using the Chromium Single Cell 134 Controller (10x Genomics) and sequencing was performed using the NextSeq High-output kit (Illumina).
135
Single cell analysis 136 Cells with ≤ 500 detected genes per cell or with ≤ 10% of transcripts corresponding to mitochondria-encoded genes were 137 removed. Low abundance genes that were detected in less than 10 cells were excluded. Each cell was normalized to a total of 138 10,000 UMI counts, and log2-transformed after the addition of 1. Top 1000 highly variable genes were selected and clusters of 139 cells were identified by the shared nearest neighbor modularity optimization based on the top 10 PCs using the highly 140 variable genes and visualized by t-SNE in R package Seurat [24] . The k-nearest neighbors (kNN) with k=10 of human cell 141 lines was detected for each mouse cell to predict subtypes of the individual cell based on signature genes of each subtype. If at 142 least 80% nearest human cell line neighbors for a mouse cell belong to one subtype, the mouse cell was assigned to that 143 subtype. Otherwise, the subtype was undetermined (not assigned).
144
Genomic analysis 145
Mutational Analysis was performed by MutSigCV V1.2 from the Broad Institute [25] . First, a dataset of merged mutation 146 calls (including coding region, germ-line filtered) from the Broad Cancer Dependency Map [26] was subsetted to only include 147 SCLC cell lines. Background mutation rates were estimated for each gene-category combination based on the observed silent 148 mutations for the gene and non-coding mutations in the surrounding regions. Using a model based on these background 149 mutation rates, significance levels of mutation were determined by comparing the observed mutations in a gene to the 150 expected counts based on the model. MutSigCV was run on the GenePattern server using this mutation BooleaBayes inference of logical relationships in the TF network 155 A Boolean function of N input variables is a function F : {0, 1} N → {0, 1}. The domain of F is a finite set with 2 N elements, 156 and therefore F is completely specified by a 2 N dimensional vector in the space {0, 1} 2 N in which each component of the F in the neighborhood of stable fixed points based on steady-state gene expression data. In practice, we let each component 160 of the vector be a continuous real-value v i ∈ [0, 1] reflecting our confidence in the output of F , based on available constraints. 161 Components of F that are near 0.5 will indicate uncertainty about whether the output should be 0 or 1, given the available 162 constraining data.
163
Given M observations (in our case, each observations is a measurement of gene expression of the N regulator TFs and the 164 target TF in M = 50 cell lines), we want to compute this vector ( V ) describing a probabilistic Boolean function F of N 165 variables (see (5) in Fig 7B) . First, we organize the input-output relationship as a binary tree with N layers leading to the 2 N 166 leaves (see (2) in Fig 7B) , each of which corresponds to a component of vector V . For instance, given two regulators A and B 167 (N = 2), the leaves of the binary tree correspond to the probabilities that (A ∧ B), (A ∧ B), (A ∧ B), and (A ∧ B).
168
Collectively, the observations define an M × N matrix R = R 1 , R 2 , . . . , R N quantifying the input regulator variables 169 (columns) for each observation (rows), as well as an M dimensional vector T = [t 1 , t 2 , . . . , t M ] quantifying the output variable 170 (see (1) in Fig 7B) . A Gaussian mixed model is then used to transform the columns of R (regulator variables) and the vector 171 T into probabilities R and T of the variables being OFF or ON in each observation (row).
172
Let P j ( R i ) be a function that quantifies the probability that the input variables of the i th observation belong to the j th leaf of the binary tree. For instance using the example above, the second leaf of the binary tree is (A ∧ B). Therefore, P j=2 (A, B) = (1 − A) · B. Note that by this definition,
that describes how much the i th observation constrains the j th component of V (see the grayscale heatmap in Fig 7B) . Additionally, to avoid overfitting under-determined leaves (columns in the grayscale heatmap with no dark cells, meaning that none of the observations constrain that leaf), we define the uncertainty U = [u 1 , u 2 , . . . , u 2 N ] of each leaf
From these, we then define the vector V describing function F as
Thus, each component of V is the average of the output target variable T weighted by W, with an additional uncertainty 173 term U to avoid overfitting. For leaves j of the binary tree that are poorly constrained by any of the observables, v j ≈ 0.5,
174
indicating maximal uncertainty in the output of F at those leaves. Uncertainty of a leaf j also arises when observations i with 175 large weight w i,j have inconsistent values for t i , such as if t 1 = 0 and t 2 = 1.
176
Results
177
Consensus Clustering uncovers new SCLC variant phenotype 178
Recently, the occurrence of variant SCLC subtypes has been reported [13, 15, 16] . Given the translational value of defining 179 subtypes, a more global approach to comprehensively define SCLC subytpes would be desirable. To this end, we devised the 180 workflow described in Fig. 1 . First, we applied Consensus Clustering [27] to RNA-seq gene expression data from the 50 SCLC 181 cell lines in the Cancer Cell Line Encyclopedia (CCLE) [28] . We clustered the cell lines using a k-means method with a 182 Pearson distance metric for k ∈ {2, 20} (Fig 2A) . Both k=2 and k=4 gave well defined clusters. Since recent literature 183 suggests that more than two subtypes are necessary to adequately describe SCLC phenotypic heterogeneity, we selected k=4 184 for further analyses.
185
To align the 4-cluster classification ( Fig 2B) with existing literature, we considered distribution of well-studied biomarkers 186 of SCLC heterogeneity across the clusters. Three of the four consensus clusters could be readily matched to subtypes 187 previously identified with 2 to 5 biomarkers: the canonical NE subtype, an NE variant subtype (referred to here as NEv1), and 188 Transcriptional patterns that distinguish the four subtypes are captured in WGCNA analysis. Gene modules by color show patterns of expression that are consistent across the subtypes. Only modules that significantly distinguish between the subtypes are shown (ANOVA, FDR-corrected p-value < 0.05). B. SCLC heterogeneity biological process phenospace. A dissimilarity score between pairs of SCLC-enriched GO terms was calculated using GoSemSim, and used to create a t-SNE projection grouping similar biological processes together. Each blue dot is a GO term, with selected terms highlighted. Several distinct clusters of related processes can be seen. C. Module-specific phenospace. A breakout of where some of the 11 statistically significant WGCNA modules fall in the GO space from A. Of particular interest, the green module, which is highly upregulated in the NEv2 phenotype, is enriched in metabolic ontologies, including drug catabolism and metabolism and xenobotic metabolism. The yellow module is enriched in canonical neuronal features. a non-NE variant subtype [10, 14, 15, 29] . However, the fourth cluster (referred to here as NEv2) could not be easily resolved 189 using only these few markers. For example, NEv2 may be considered a tumor propagating cell (TPC) by biomarkers in Jachan 190 et al [23] , yet expression of HES1 may suggest grouping into a non-NE subtype by Lim et al [10] . This discrepancy drove us 191 to consider broader patterns of gene expression, rather than a limited number of biomarkers, to characterize each subtype.
192
SCLC phenotypes are differentially enriched in diverse biological processes, including drug 193 catabolism and immuno-modulation 194 To capture global gene expression patterns, we applied Weighted Gene Co-expression Network Analysis (WGCNA) [30] to 195 RNA-seq data from CCLE for multiple SCLC cell lines (See methods). This analysis revealed 17 groups, or modules, of 196 co-expressed genes. Module eigengenes could be used to describe trends of gene expression levels. 11 of these 17 groups of 197 co-expressed genes could statistically distinguish between the four consensus clusters ( Fig 3A, Table S1 , Kruskal-Wallis,
198
FDR-adjusted p < 0.05). To specify the biological processes enriched in each of these 11 gene modules, we performed gene 199 ontology (GO) enrichment analysis using the Consensus Path Database [31] , which resulted in a combined total of 1,763 200 statistically enriched biological processes (Table S2 , Fig 3B) . In particular, the yellow, salmon, and pink modules are enriched 201 for neuroendocrine differentiation and neurotransmitter secretion and are upregulated in the canonical NE and NEv1 202 phenotypes ( Fig 3C) . In contrast, the blue, black, and purple modules, enriched for cell adhesion and migration processes, are 203 upregulated in the non-NE variant phenotype, in agreement with the observed adherent culture characteristics of these cell 204 lines.
205
Genes within the brown, midnight blue, and green modules are upregulated in the NEv2 phenotype. The brown module is 206 enriched for canonical phenotypic features of SCLC, particularly cellular secretion and epithelial differentiation, and 207 accordingly is also upregulated in the canonical NE subtype. The midnight blue module, enriched in nervous system processes 208 and lipid metabolism, is highly expressed in the NEv2 cell lines. The green module is enriched for immune/inflammatory 209 response, wound healing, homeostasis, drug/xenobiotic metabolism, and cellular response to environmental signals ( Fig 3C) . 210 Enrichment of these GO terms suggest that NEv2 cells may more easily adapt to external perturbations such as therapeutic 211 agents, and potentially show higher drug resistance.
212
To visualize these enriched GO terms in an organized way ( Fig 3B) , we used the GOSemSim package [20] in R to compute 213 a pairwise dissimilarity score, or distance, between all enriched GO terms (FDR-adjusted p < 0.05 in at least one of the 11 214 significant modules). We then projected all significant GO terms into a 2D space by t-distributed stochastic neighbor 215 embedding (t-SNE) [32] . In this t-SNE projected phenospace, GO terms that describe semantically similar biological 216 processes are placed close to one another and grouped into a general biological process. This map allows exploration of 217 biological processes enriched in individual gene modules or subtypes, and it shows that SCLC heterogeneity spans biological 218 processes that can largely be grouped as 1) related to neuronal, endocrine, or epithelial differentiation; 2) metabolism and 219 catabolism; 3) cell-cell adhesion and mobility; and 4) response to environmental stimuli, including immune and inflammatory 220 responses. In summary, the phenospace constructed from global gene expression patterns captures the unique characteristics 221 No significant differences can be seen in response to etoposide and platinum-based agents cisplatin and carboplatin, the standard of care for SCLC. C-F. Significantly differential response by ANOVA, p < 0.05, shown in drugs that target C. mTOR, D. HSP90, E. BRD2, and F. AURKA. NEv2 is significantly more resistant to all of these drugs. As mentioned previously, the enriched GO terms for drug catabolism and xenobiotic metabolism in the green module suggest 224 that the NEv2 phenotype may have a higher ability to metabolize drugs and therefore exhibit decreased sensitivity. To test 225 this possibility, we reanalyzed drug responses of SCLC cell lines to a panel of 103 FDA-approved oncology agents and 423 226 investigational agents in the context of our four subtype classification [21] . We used the Activity Area (AA) metric as a 227 measure of the resultant dose-response curves. The drugs were analyzed individually and clustered by common mechanism of 228 action and target type, and the cell lines were grouped by the four subtypes (Table S3 ). Across all evaluated drugs, the NEv2 229 subtype exhibited the most resistance (54% cell lines were resistant). In contrast, both NE and NEv1 exhibited less resistance 230 (20% cells were resistant), with non-NE exhibiting the least resistance (6% of cell lines were resistant) ( Fig 4A) . Taken 231 together, these results confirm that based on the prediction from the gene-regulation based classification, the subtypes exhibit 232 different levels of resistance and that high resistance is a feature of the NEv2 subtype ( Fig 32C) . In particular, mTOR 233 inhibitors are a class of compounds to which NEv2 was significantly more resistant (Fig 4) . PI3K pathway mutations have 234 previously been implicated as oncogenic targets for SCLC, as about a third of patients show genetic alterations in this 235 pathway [33] . Among the four subtypes, NEv2 is also the least sensitive to AURKA, B, and C inhibitors (AURKA shown); 236 TOPO2 inhibitors; and HSP90 inhibitors (Fig 4) . These results have implications for interpreting expected or observed 237 treatment response with respect to tumor heterogeneity in individual patients.
238
Neuroendocrine variants are represented in mouse and human SCLC tumors 239 Next, we investigated whether the four subtypes we detected in human SCLC cell lines are also present in tumors. We used 240 CIBERSORT [4] to generate gene signatures for each of the 4 subtypes. These gene signatures could then deconvolve 241 RNA-seq measurements on 81 SCLC tumors from George et al [5] to specify relative prevalence of each subtype within a 242 single tumor. CIBERSORT predicted that a majority of tumors were comprised of all four subtype signatures, in varying 243 proportions across tumor samples ( Fig 5A) . We then analyzed the patient/cell-derived xenograft models (PDXs/CDXs) 244 developed by Drapkin et al [18] , and the tumors also showed vast differences across samples ( Fig 5B) . Some of these samples 245 were taken across multiple time points from the same patient, thus enabling us to test both tumor composition and dynamic 246 changes in tumor subpopulations. Three samples taken from patient MGH1514, before and after treatment, indicated a 247 change in tumor composition in favor of the NE phenotype. In contrast, patient MGH1518 showed a reduction of NEv1 and 248 increase in NEv2 after treatment. Overall, the high variance in proportions of each subtype suggest a high degree of 249 intertumoral, as well as intratumoral, dynamic heterogeneity and plasticity. 250 We also investigated phenotypic patterns in mouse tumors from two different sources to determine whether human SCLC 251 subtype signatures are conserved across species [15] (Supplemental Methods). The first mouse model is a triple knockout 252 (Rb1, Tp53, and P130, conditionally deleted in lung cells via a Cre-Lox system, TKO), and these tumors were primarily 253 composed of the NE and NEv2 subtypes (Fig 6Ai) . Of note is the lower percentage of non-NE cells found in each tumor in 254 Fig 6Ai; we suspect this is due to a filtering step before sequencing (Supplemental Methods), as the non-NE subtype 255 signature is more similar to tumor-associated immune cells in an unfiltered tumor population. The second mouse model was 256 generated with Myc overexpression (double knockout of Rb1 and Tp53, and overexpression of MYC) (Fig 6Aii) as reported 257 previously [15] . Using the subtype gene-signatures developed in the previous sections, the Myc-high tumors showed a clear 258 increase in the percentage of NEv1 detected compared to the triple knockout tumors in Fig 6Ai, corroborating the correlation 259 between NEv1 and a previously described Myc-high mouse tumor subtype.
260
Lastly, we analyzed two primary TKO mouse tumors by single cell RNA-seq (scRNA-seq). For each mouse single cell 261 transcriptome, we computed the k=10 nearest human cell line neighbors (kNN with k=10), and assigned each mouse cell to a 262 subtype based on its neighbors (Supplemental methods). As shown in Fig 6B, a large portion of the cells from each tumor 263 correspond to one of the four human subtypes. A small non-NE population can be seen in both tumors, and about a third of 264 the assigned cells correspond to the NE subtype ( Fig 5B) . Tumor A has a large proportion of the NEv2 subtype, 265 corresponding to the tumors in 5Ai. In contrast, tumor B has a large NEv1 subpopulation, similar to the tumors in 5Aii.
266
Taken together, these results indicate that subtypes in SCLC tumors are conserved across species, and can be categorized 267 either by CIBERSORT analysis of bulk transcriptomics data, or by kNN analysis of scRNA-seq data.
268
Genetic mutations alone cannot account for four SCLC phenotypes 269 The evidence above for intratumoral and intertumoral heterogeneity led us to investigate how the subtypes arise and coexist 270 in both human and mouse SCLC tumors. To determine whether mutations could be responsible for defining the four SCLC 271 subtypes, we analyzed genomic data in the Broad Cancer Dependency Map [26] . We subsetted these data to the 50 SCLC cell 272 lines with matching CCLE RNA-seq data, and using MutSigCV [25] , we found 29 genes (S2 Fig To investigate these alternative sources of heterogeneity, we hypothesized that different SCLC subtypes emerge from the 278 dynamics of an underlying TF network. We previously identified a TF network that explained NE and non-NE SCLC subtype 279 heterogeneity [16] . That analysis suggested the existence of additional SCLC subtypes but did not specify corresponding 280 attractors [16] . Here, we performed an expanded TF network analysis to find stable attractors for all four SCLC subtypes. As 281 an initial step, we identified putative master TF regulators within each of the 11 WGCNA modules ( Fig 3B) based on 282 differential expression. Regulatory interactions between these TFs were extracted from public databases, including ChEA, 283 TRANSFAC, JASPAR, and ENCODE, based on evidence of TF-DNA binding sites in the promoter region of a target TF, as 284 well as several sources from the literature. This updated network largely overlaps with, but contains several refinements 285 compared to our previous report [16] , as detailed in Fig 7A. 286 Following the procedure we previously used [16] , we simulated the network using threshold and inhibitory dominant 287 update rules. These update rules are commonly used as coarse-grained approximations of systems for which detailed 288 biological regulatory functions are unknown. However, these approximations were not sufficient to stabilize attractors 289 corresponding to either the NEv1 or NEv2 phenotypes (data not shown), suggesting that the regulatory rules governing 290 stability of these phenotypes are more complex.
291
To understand this, we developed BooleaBayes, a method to infer logical relationships in gene regulatory networks ( Red edges indicate inhibition (on average), and green activation (on average). B. Probabilistic Boolean rule fits for ASCL1. The target gene is a function of all the genes along the binary tree at the top, while expression of the target is shown on the left. Each row represents one cell line, each column represents one possible input state, and the bottom shows the inferred function F for every possible input state. Color ranges from 0=blue (highly confident the TF is off), to 0.5 = white, to 1=red (highly confident the TF is on). Rows are organized by subtype (top to bottom: NE, NEv1, NEv2, non-NE). C. Attractors found with asynchronous updates of Boolean network. 10 attractors were found, and each correlates highly with one of the four subtypes (represented by stars). Specifics of the probabilistic simulation are described in Results.
( Fig 7C) . An advantage of this method is that it makes predictions intrinsic to those parts of the network in which we are 295 most confident (Supplemental Methods). 296 BooleaBayes rules (probabilistic logical relationships between connected nodes) were derived for each node of the SCLC 297 TF network in Fig 7A. As an example, Fig 7B shows the rule fitting for one node, ASCL1. Rules for all other nodes are given 298 in Supplemental Fig 4. We simulated the dynamics of the Boolean network using a general-asynchronous update scheme [34] . 299 This formed a state transition graph (STG), in which each state is defined by a vector of TF ON/OFF expression values.
300
For the initial states in the simulation, we discretized the average TF expression for each of the four SCLC subtypes. We 301 exhaustively searched the neighborhood of each of these starting states out to a distance of 6 TF changes in the STG. Within 302 these neighborhoods, we found 10 states for which all 27 TFs had at least a 50% chance of remaining unchanged. Transitions 303 into these states are therefore more likely, and escapes less likely. Thus, these 10 states represent semi-stable states of the 304 network dynamics (Fig 7C) , that we refer to as pseudo-attractors. To quantify the baseline stability of the steady states in Fig 7C, we performed random walks (algorithm described in 313 Supplemental Methods) starting from each of the 10 pseudo-attractors. We counted how many steps were required to reach a 314 state outside of a 4-TF neighborhood around the starting state (Fig 8) . We chose a 4-TF neighborhood for a given attractor 315 because a randomly chosen state has only a 2.5% chance of falling within this neighborhood, suggesting states in this 316 neighborhood are significantly similar to the attractor state (p = 0.025). Each TF in the network was either activated (held 317 constant at TF=1) or silenced (TF=0) in each of the stable states, and 1000 random walks were executed for each condition 318 ( Fig 8A) . The percent increase or decrease of the stability relative to the unperturbed reference was calculated, resulting in a 319 score quantifying (de)stabilization of the starting state by each TF perturbation (Fig 8B, Fig S3) . For example, either 320 activation of GATA4 (TF = 1) or silencing FOXA1 (TF=0) are predicted to destabilize both the NE and NEv2 subtypes (Fig 321  8C) .
322
TFs that, when silenced, cause destabilization greater than 20% (score ≤ -0.2) of a specific subtype were considered 323 master regulators of that subtype. They include REST (non-NE) (in agreement with [10] , TEAD4 (non-NE), ISL1 (NE), 324 and TCF4 (NEv1). TEAD4 is downstream mediator of YAP1 action, which has been previously identified as a possible 325 phenotypic modulator in a subset of SCLC cell lines [35] ; our analyses suggest that expression of TEAD4 may be able to 326 stabilize this phenotype. Simulations of the network also identified the novel NEv2 master regulators, ELF3 and NR0B1.
327
Our network simulations further identified TFs that can be considered master "destabilizers", i.e., activation of these TFs 328 destabilizes a specific phenotype by at least 20%. For instance, activation of ELF3 is predicted to destabilize non-NE, while 329 activation of NR0B1 would destabilize both non-NE and NE subtypes. Simulations identified a single master destabilizer for 330 NEv2, the TF TCF3 ( Fig 8C) . Taken together, our pipeline, which includes subtype identification, drug response analysis, 331 and network simulations, suggests possible therapeutic perturbations that could shift the phenotypic landscape of SCLC into 332 a more sensitive state for treatment. Fig 4C will eventually leave the start state due to uncertainty in the Boolean rules. Reference histogram shows how many random steps are required for a distance greater than 4 TF changes away from the start state under the network's natural dynamics. The knockdowns and activations shown here hold expression of the perturbed gene OFF or ON. The perturbation destabilizes the start state, such that the random walk leaves the neighborhood sooner, shown for NE, NEv1, NEv2, and non-NE starting states. B. Stabilization of SCLC phenotype NEv2 by TF activation and knockdown. The percent change of stability measures the percent change in the average number of steps needed to leave the neighborhood of the stable states. Negative indicates destabilizing, while positive indicates increasing stability. Results are shown for 1000 iterations starting from NEv2. Similar plots for the other subtypes can be found in Fig S3. C. A Venn diagram demonstrating overlap of destabilization strategies. A single activation (green text) or knockdown (red text) can sometimes destabilize multiple phenotypes. TF perturbations that have a stabilization score of less than -0.2 were considered destabilizing.
Discussion
334
We report a systems approach to understanding SCLC heterogeneity that integrates transcriptional, mutational, and 335 drug-response data. Our findings culminate in discrimination and mechanistic insight into the four SCLC subtypes shown in 336 Table 1 : NE, non-NE, NEv1, and NEv2. Within the context of the broader literature on SCLC heterogeneity, we showed that 337 NE, non-NE, and NEv1 correspond to several subtypes that have been previously reported based on a few markers.
338
Significantly, we find that one (NEv2) has not been described previously, and which is nearly indistinguishable from NE based 339 on currently used markers of SCLC heterogeneity.
340
Tumor deconvolution by CIBERSORT and analysis of scRNA-seq data indicate that this subtype is present in a large 341 proportion of human and mouse SCLC tumors. Moreover, a drug screen across a broad range of compounds indicated that 342 this subtype is more resistant than the others, especially in response to AURK and mTOR inhibitors. Direct experimental 343 verification in mouse and human tumors of the NEv2 subtype's drug resistant properties will be an important next step. For 344 example, the PDXs from patient MGH1518 before and after drug show an increase in the NEv2 signature ( Fig 5B) , which 345 may be responsible for acquired drug-resistance in this patient. However, this study was under-powered for our analyses, and 346 more experimental data will be necessary to strengthen this conclusion.
347
A significant advance of our work is the introduction of BooleaBayes, which we developed to infer mechanistic insights into 348 regulation of the heterogeneous SCLC subtypes. By considering the distinct subtype clusters as attractors of a gene 349 regulatory network, BooleaBayes infers partially-constrained mechanistic models. A key benefit of this method is that it does 350 not overfit data: predictions are based only on parts of the network for which available data can constrain the dynamics, 351 while states that lack constraining data diffuse randomly. With this method we were able to recapitulate known master 352 regulators of SCLC heterogeneity, as well as identify novel ones such as ISL1 (NE) and TEAD4 (non-NE). Additionally, we 353 predict ELF3 and NR0B1 to be master regulators of the NEv2 phenotype. Furthermore, we introduce the label of "master 354 destabilizers" to describe TFs whose activation will destabilize a phenotype. Our method gives a systematic way to rank 355 perturbations that may destabilize a resistant phenotype. In ongoing work, we are validating these predictions experimentally. 356 We propose that with BooleaBayes, our approach for identifying master TFs could be applicable to other systems, including 357 other cancer types or transcriptionally-regulated diseases.
358
While many of the previously reported subtypes of SCLC fit into our framework, a few are noticeably absent, and will 359 require further study. The vasculogenic subtype of SCLC described by Williamson et al. [36] did not emerge from our analysis. 360 We speculate that this may be due to the rarity and/or instability of this CTC-derived phenotype among the available SCLC 361 cell lines. Denny and Yang et al. have previously reported that Nfib amplification promotes metastasis [37] ; however, our 362 clusters do not correlate with location of the tumor sample from which each cell line was derived (e.g., primary vs metastatic, 363 data not shown). Poirier et al., using a similar clustering approach to ours, identified highly methylated SCLC subtypes (M1 364 and M2) [29] , and the correspondence of these subtypes with the ones described here is intriguing and remains to be defined. 365 Finally, Huang et al. recently reported an SCLC subtype defined by expression of POU2F3 [12] . In our data, POU2F3 was 366 highly expressed in only four cell lines, and was placed POU2F3 into a small (328 genes, green-yellow) module, and therefore 367 represented only a small signal in our data. Overall, future studies with additional cell line and/or mouse data may be used 368 to further investigate these different subtypes, underscoring that the delineation of four subtypes here does not preclude the 369 existence of others. 370 
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Conclusion
371
An advantage of our analyses is that each subtype is defined by distinct co-expressed gene programs, rather than by 372 expression of one or few markers, which has been customary in the field but has limited ability to discriminate between 373 phenotypes ( Fig 2B) . In addition, these modules participate in unique biological processes (e.g., as identified by GO), such 374 that the systems-level approach presented here may provide a comprehensive framework to understand the regulation and 375 functional consequences of SCLC heterogeneity in a tumor. This understanding can be actionable since SCLC subtypes show 376 differential drug sensitivity; for example, our analyses in this paper support the hypothesis that NEv2 may be a drug-resistant 377 phenotype of SCLC. We propose that identification of drugs targeting the NEv2 subtype, or perturbagens that reprogram it 378 toward less recalcitrant states, may lead to improved treatment outcomes for SCLC patients. shows slight inconsistency for cell lines with k=3. One of these is assigned to the "light green" cluster in the k=3 clustering 382 scheme, whereas when k=4, it returns to the "light blue" cluster. The others are in the "dark blue" cluster when k=2 and 383 "light blue" cluster when k = 3. B. The delta area plot shows the relative change in the area under the CDF curve ( Fig 1A) . 384 The largest changes in area occur between k=2 and k=4, at which point the relative increase in area becomes noticeably 385 smaller (from an increase of 0.5 and 0.4 to 0.15). This suggests that k=4,5, or 6 are the best clustering that maximizes 386 detail (more, smaller clusters present a more detailed picture than a few large clusters) and minimizes noise (by minimizing 387 11/14 average pairwise consensus values and maximizing extreme pairwise consensus values. Average cluster consensus scores (CCS) 388 across clusters show that k=4 may be the best choice because it has the highest average (k = 4 average CCS: 0.848, k=5 389 average CCS: 0.814, k=6 average CCS: 0.762). C. Consensus Cumulative Distribution Function. This CDF show that k=4 390 has more black cells and white cells than gray, suggesting the consensus clusters are more robust. Inspection by eye shows that no significant mutations can distinguish completely between two or more phenotypes. This The parent nodes of this sample from are best represented by the gray path: OLIG2 OFF, TEAD4 OFF, FLI1 ON, and so on. Because the gray path best represents the sample, the column below the gray path intersects the green row at the pink square, so this square is shaded darker, representing a higher weight. This is continued for each sample (row). The orange column shows the weights associated with the gray path for one state of the parent nodes. By multiplying the expression of the left column by the matrix of weights, the rule (bottom) is produced. For example, since most of the higher weights in the orange column are in rows with red (high) expression, the inferred rule for the state suggests that ASCL1 should be ON when OLIG2 is OFF, TEAD4 is OFF, FLI1 is ON, and so on. 1 B.
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